Moreover, exposure of HER2 and EPOR dual-positive breast cancer cell lines to trastuzumab inhibited AKT and ERK phosphorylation, but the inhibition was reduced by simultaneous treatment with recombinant EPO. This evidence concerns the gene EPO and breast cancer.